导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.13% | 1938/4773 |
| 近一周 | -2.09% | 1201/5462 |
| 近一月 | -6.04% | 3426/5421 |
| 近一季 | -10.40% | 3480/5209 |
| 近半年 | -8.34% | 3336/4920 |
| 近一年 | 9.73% | 1063/4366 |
| 近两年 | 83.70% | 752/2954 |
| 近三年 | 50.65% | 525/2253 |
| 成立以来 | 149.76% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
4.15% 575/4961 |
12.10% 2232/5312 |
- - |
- - |
| 2025 | 43.01% 683/4813 |
3.71% 1050/3635 |
3.61% 978/4076 |
26.97% 1320/4524 |
4.82% 480/4813 |
| 2024 | 5.54% 1826/3463 |
-5.85% 1958/2808 |
-2.10% 1135/3014 |
13.09% 2247/3129 |
1.25% 1097/3463 |
| 2023 | 4.01% 249/2656 |
10.42% 366/2280 |
-3.32% 770/2385 |
-1.10% 483/2515 |
-1.48% 333/2655 |
| 2022 | -18.66% 739/2207 |
-12.20% 586/1919 |
6.14% 765/2016 |
-12.90% 804/2113 |
0.22% 1523/2208 |
| 2021 | 26.46% 98/1822 |
3.04% 200/1255 |
16.70% 194/1330 |
5.23% 286/1466 |
-0.07% 1194/1822 |
| 2020 | 30.30% 523/1250 |
-5.15% 401/1028 |
20.69% 263/1067 |
12.07% 407/1164 |
1.56% 1023/1184 |
| 2019 | 35.60% 372/1092 |
29.35% 279/739 |
-5.50% 469/788 |
1.82% 354/850 |
8.95% 270/918 |
| 2018 | - - |
- - |
- - |
- - |
-15.54% 613/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 长城中证500指数增强A VS. 长安沪深300非周期A(740101) |